BioXcel Therapeutics Completes $8M Registered Direct Offering

miércoles, 11 de marzo de 2026, 4:21 pm ET1 min de lectura
BTAI--

BioXcel Therapeutics has closed an $8.0 million registered direct offering, issuing 4,500,785 shares of common stock and accompanying warrants to purchase up to 4,500,785 shares of common stock. The warrants have an exercise price of $1.614 per share and expire five years from issuance. The company also reduced the exercise price of existing warrants to $1.614 per share and extended their expiration dates.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios